Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Selinexor/Ruxolitinib Combo Shows Early Activity, Tolerability in Treatment-Naïve Myelofibrosis

July 25th 2022

A combination comprised of selinexor (Xpovio) and ruxolitinib (Jakafi) induced rapid spleen responses at week 12 and showcased a manageable toxicity profile in patients with treatment-naïve myelofibrosis.

Risk Stratification for Myelofibrosis

July 22nd 2022

The panel has a conversation on risk stratification for myelofibrosis and how it individualizes their treatment approaches.

Myeloproliferative Neoplasms: Myelofibrosis

July 22nd 2022

Dr Jamile Shammo explains the process of diagnosing myelofibrosis and highlights the importance of bone marrow biopsies.

Eltanexor Gets FDA Fast Track Status and Orphan Medicinal Product Designation in Europe for MDS

July 21st 2022

Eltanexor has been granted a fast track designation from the FDA and an orphan medicinal product designation from the European Commission for use as a potential therapeutic option in patients with myelodysplastic syndromes.

Assessing Symptom Burden and Quality-of-Life for Myeloproliferative Neoplasms

July 13th 2022

A discussion on assessing symptom burden and quality of life for patients with essential thrombocythemia or polycythemia vera.

PTG-300 Therapy for Phlebotomy-Dependent Polycythemia Vera

July 13th 2022

Ruben Mesa, MD, details an abstract presented at ASCO 2022 on an investigational agent filling an unmet need in polycythemia vera.

Dr. Rampal on the Potential Utilization of Navtemadlin in Relapsed/Refractory AML and MPNs

July 6th 2022

Raajit K. Rampal, MD, PhD, discusses the potential utilization of navtemadlin in relapsed/refractory acute myeloid leukemia and patients with blast phase myeloproliferative neoplasm in a phase 1b/2 trial.

Treatment Options for Polycythemia Vera

July 6th 2022

An overview of the treatment options for patients with polycythemia vera.

Myeloproliferative Neoplasms: Polycythemia Vera

July 6th 2022

Jamile Shammo, MD, FACP, FASCP, defines polycythemia vera and explains the process for diagnosis and risk stratification.

Future Perspectives in Higher-Risk MDS

July 6th 2022

Dr Gustavo Rivero comments on novel treatment combinations and potential new biomarkers in patients with MDS.

Managing Patients with Essential Thrombocythemia

June 29th 2022

Dr Ruben Mesa describes how he treats patients with essential thrombocythemia and the available treatment options.

Myeloproliferative Neoplasms: Essential Thrombocythemia

June 29th 2022

Jeanne Palmer, MD, explains essential thrombocythemia and how it’s diagnosed.

SELECT-MDS-1: Review of Study Design and Objectives

June 28th 2022

Gustavo Rivero, MD, comments on the ongoing SELECT-MDS-1 trial and as well as reviewing the adverse events of the potential combination of tamibarotene with azacitidine in patients with higher-risk MDS.

A Potential Role for Tamibarotene in the Treatment of Higher-Risk MDS

June 28th 2022

Dr Gustavo Rivero reviews the treatment options for patients with newly diagnosed higher-risk MDS and discusses tamibarotene’s recent orphan drug designation.

Clinical Pearls for the Management of Myelofibrosis

June 23rd 2022

Closing out their discussion on myelofibrosis, experts provide practical advice for identifying and managing patients in real-world practice.

Guadecitabine Fails to Improve OS Over Physician’s Choice of Treatment in MDS and CMML

June 21st 2022

Guadecitabine did not result in a statistically significant improvement in overall survival compared with physician’s choice of treatment in patients with relapsed/refractory myelodysplastic syndrome or chronic myelomonocytic leukemia, according to data from the phase 3 ASTRAL-3 trial.

Fedratinib with GI Prophylaxis Has Tolerable Safety Profile in Myelofibrosis After Prior Ruxolitinib

June 17th 2022

Fedratinib was shown to be generally well tolerated in older patients with myelofibrosis who had received at least 3 months of prior ruxolitinib, according to findings from the phase 3b FREEDOM trial.

FDA Approval Sought for Momelotinib in Myelofibrosis

June 17th 2022

A new drug application seeking the approval of momelotinib for the treatment of patients with myelofibrosis has been submitted to the FDA.

RARA Gene Expression in Higher-Risk MDS

June 17th 2022

Dr Gustavo Rivero talks about the significance of the RARA gene in patients with higher-risk MDS.

Overview of Myelodysplastic Syndrome and the Importance of Biomarker Testing

June 17th 2022

An overview of myelodysplastic syndrome (MDS) and the role of biomarker testing in patients with the disorder.